ProQR Therapeutics N.V. (PRQR)

Market Cap	264.20M
Revenue (ttm)	20.51M
Net Income (ttm)	-26.70M
Shares Out	103.20M
EPS (ttm)	-0.33
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	163,594
Open	2.550
Previous Close	2.580
Day's Range	2.500 - 2.660
52-Week Range	1.610 - 4.620
Beta	0.25
Analysts	Strong Buy
Price Target	8.17 (+219.14%)
Earnings Date	Mar 12, 2025

About PRQR

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company’s products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepati...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 18, 2014
• Employees: 157
• Stock Exchange: NASDAQ
• Ticker Symbol: PRQR
• Website: https://www.proqr.com

Financial Performance

In 2023, ProQR Therapeutics's revenue was 6.59 million, an increase of 51.27% compared to the previous year's 4.36 million. Losses were -28.12 million, -56.35% less than in 2022.

Financial numbers in EUR

Analyst Forecast

According to 6 analysts, the average rating for PRQR stock is "Strong Buy." The 12-month stock price forecast is $8.17, which is an increase of 219.14% from the latest price.

Price Target

$8.17

(219.14% upside)

Analyst Consensus: Strong Buy